In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...
Nov 16, 2018
0
37
A new study describes a compound that selectively kills cancer cells by restoring the structure and function of one of the most commonly mutated proteins in human cancer, the "tumor suppressor" p53. The research, published ...
May 14, 2012
0
0
Scientists at the University of Massachusetts Medical School have shown that diffuse large B-cell lymphoma (DLBCL) may be susceptible to treatment by re-activating the normal aging program in tumor cells so they can no longer ...
Oct 14, 2013
0
0
University of Toronto researchers have uncovered why some cancers grow faster than others. The team led by Liliana Attisano, Professor in U of T's Donnelly Centre for Cellular and Biomolecular Research, has identified a protein ...
Aug 29, 2018
0
241
Aggressive cancer growth and alterations in gene activity without changes in DNA sequence (epigenetics) are associated with mutant p53 proteins, according to new research from the Perelman School of Medicine at the University ...
Sep 2, 2015
1
139
A brain protein with high potential to delay or reverse the onset of Alzheimer's disease has been exploited by University of Otago researchers.
Aug 1, 2022
0
25
Loud noise, especially repeated loud noise, is known to cause irreversible damage to the hair cells inside the cochlea and eventually lead to deafness. In mammals this is irreversible, however both birds and fish are able ...
Sep 2, 2011
0
0
Researchers at University of California, San Diego School of Medicine have discovered a self-regulating loop in the Hippo pathway, a signaling channel garnering increased attention from cancer researchers due to its role ...
Jun 26, 2015
0
116
Varicose veins, sometimes referred to as "varices" in medical jargon, are usually just a cosmetic problem if they occur as spider veins. In their advanced stage, however, they pose a real health threat. In people with this ...
Nov 4, 2011
0
1
An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...
Dec 11, 2011
0
0
